Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months
Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
Clinical Trial Summary
The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is:
\- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children?
Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency.
Participants will:
* Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days.
* Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice.
* Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.